A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
Clinical trial NCT04636814 · TERMINATED
Trial details
- NCT number
- NCT04636814
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-12
- Primary completion
- 2025-12-23
- Enrollment
- 3973
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.